𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Results of the Southwest Oncology Group phase II evaluation (study S0031) of ZD1839 for advanced transitional cell carcinoma of the urothelium

✍ Scribed by Daniel P. Petrylak; Catherine M. Tangen; Peter J. Van Veldhuizen Jr; J. Wendall Goodwin; Przemyslaw W. Twardowski; James N. Atkins; Shaker R. Kakhil; Marianne K. Lange; Mahesh Mansukhani; E. David Crawford

Book ID
109056080
Publisher
John Wiley and Sons
Year
2010
Tongue
English
Weight
260 KB
Volume
105
Category
Article
ISSN
1464-4096

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Phase II trial of carboplatin and paclit
Phase II trial of carboplatin and paclitaxel in cisplatin-pretreated advanced transitional cell carcinoma : A Southwest Oncology Group study
✍ Ulka N. Vaishampayan; James R. Faulkner; Eric J. Small; Bruce G. Redman; Wayne L πŸ“‚ Article πŸ“… 2005 πŸ› John Wiley and Sons 🌐 English βš– 86 KB

## Abstract ## BACKGROUND The purpose of the study was to assess the efficacy and toxicity of carboplatin and paclitaxel administered every 3 weeks in patients with advanced urothelial carcinoma, previously treated with cisplatin‐based therapy. ## METHODS Eligibility included metastatic or local

Phase II evaluation of mitoxantrone in a
Phase II evaluation of mitoxantrone in advanced pancreatic carcinoma: A Southwest Oncology Group study
✍ Sarah A. Taylor; Thomas Fleming; Daniel D. Hoff; Joseph D. McCracken; Ronald M. πŸ“‚ Article πŸ“… 1990 πŸ› Springer US 🌐 English βš– 242 KB

Patient with advanced adenocarcinoma of the pancreas and no prior chemotherapy were treated on a Phase II trial of mitoxantrone. Doses were adjusted for hepatic dysfunction as defined by bilirubin. Twenty-four patients with a bilirubin less than or equal to 1.5 mg% received mitoxantrone 12 mg/m2 i.v